Section of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, 11211, Saudi Arabia.
College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia.
BMC Endocr Disord. 2023 Apr 7;23(1):74. doi: 10.1186/s12902-023-01326-1.
Gastroenteropancreatic Neuroendocrine tumors (GEP-NET) are rare neoplasms with limited reported data from the Middle East. Our study aims to report the clinicopathological feature, treatment patterns, and survival outcomes of patients with GEP-NET from our part of the world.
Medical records of patients diagnosed with GEP-NET between January 2011 and December 2016 at a single center in Saudi Arabia were reviewed retrospectively, and complete clinicopathological and treatment data were collected. Patients' survival was estimated by the Kaplan-Meier method.
A total of 72 patients were identified with a median age of 51 years (range 27-82) and male-to-female ratio of (1.1). The most common tumor location was the pancreas (29.1%), followed by small bowel (25%), stomach (12.5%), rectum (8.3%), colon (8.3%), and appendix (6.9%). Forty-one patients (57%) had well-differentiated grade (G)1, 21 (29%) had G2, and 4 (6%) had G3. In five patients, the pathology was neuroendocrine carcinoma and in one it could not be classified. 54.2% of the patients were metastatic at diagnosis. Forty-two patients underwent surgical resection as primary management while 26 underwent systemic therapy, three patients were put on active surveillance, and one was treated endoscopically with polypectomy. The 5-year overall survival and progression-free survivals were 77.2% and 49%, respectively, for the whole group. Patients with G1 and 2 disease, lower Ki-67 index, and surgically treated as primary management had significantly better survival outcomes.
Our study suggests that the most common tumor locations are similar to western reported data. However, there seems to be a higher incidence of metastatic disease at presentation than in the rest of the world.
胃肠胰神经内分泌肿瘤（GEP-NET）较为罕见，来自中东地区的相关报告数据有限。本研究旨在报告我们所在地区 GEP-NET 患者的临床病理特征、治疗模式和生存结果。
回顾性分析 2011 年 1 月至 2016 年 12 月在沙特阿拉伯的一家单中心诊断为 GEP-NET 的患者的病历，收集完整的临床病理和治疗数据。使用 Kaplan-Meier 法估计患者的生存情况。
共确定 72 例患者，中位年龄为 51 岁（范围 27-82 岁），男女性别比为 1.1。最常见的肿瘤部位是胰腺（29.1%），其次是小肠（25%）、胃（12.5%）、直肠（8.3%）、结肠（8.3%）和阑尾（6.9%）。41 例（57%）患者的组织学分级为 1 级（G1），21 例（29%）为 G2，4 例（6%）为 G3。5 例患者的病理为神经内分泌癌，1 例无法分类。54.2%的患者在诊断时发生转移。42 例患者接受了手术切除作为初始治疗，26 例患者接受了系统治疗，3 例患者接受了主动监测，1 例患者接受了内镜下息肉切除术。全组患者的 5 年总生存率和无进展生存率分别为 77.2%和 49%。G1 和 2 级疾病、较低的 Ki-67 指数和手术作为初始治疗的患者生存结果显著更好。
本研究表明，最常见的肿瘤部位与西方报道的数据相似。然而，与世界其他地区相比，患者在就诊时似乎有更高的转移疾病发生率。
